Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review

Fig. 3

Descriptive presentation of the annual rate of moderate and severe exacerbations for within-trial comparisons. B budesonide, BDP beclomethasone, CI confidence interval, COPD chronic obstructive pulmonary disease, FF fluticasone furoate, FOR formoterol fumarate, FULFIL Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy, GLY glycopyrronium bromide, ICS inhaled corticosteroids, IMPACT InforMing the PAthway of COPD Treatment, IND indacaterol, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist, NA not available, NNT number needed to treat, TIO tiotropium, UMEC umeclidinium, VI vilanterol. #Calculated. Estimated from graph. +A 24-week study. Rate ratios, 95% CIs and NNT for annual rate of moderate and severe exacerbations between triple therapy and comparators, overall and by subgroups for each within-trial comparison of triple therapy and LAMA/LABA, LABA/ICS and LAMA. Cross-trial comparisons are descriptive only. NNT were only calculated for 52-week studies, ~ numbers used in calculation estimated from graph

Back to article page